{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T09:39:19Z","timestamp":1793612359845,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":47,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["314061271"],"award-info":[{"award-number":["314061271"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["314061271 - TRR205"],"award-info":[{"award-number":["314061271 - TRR205"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR205"],"award-info":[{"award-number":["TRR205"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.beem.2024.101955","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T16:36:44Z","timestamp":1727282204000},"page":"101955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Current views on the role of HIF-2\u03b1 in the pathogenesis and syndromic presentation of pheochromocytoma and paraganglioma"],"prefix":"10.1016","volume":"38","author":[{"given":"Nicole","family":"Bechmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared S.","family":"Rosenblum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali S.","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2024.101955_bib1","article-title":"Pheochromocytoma and paraganglioma","author":"Pacak","year":"2018","journal-title":"Endotext"},{"key":"10.1016\/j.beem.2024.101955_bib2","author":"Else","year":"2018","journal-title":"Hered Paraganglioma-Pheochromocytoma Syndr"},{"issue":"4","key":"10.1016\/j.beem.2024.101955_bib3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1530\/ERC-21-0359","article-title":"Head\/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine","volume":"29","author":"Richter","year":"2022","journal-title":"Endocr-Relat Cancer"},{"issue":"7","key":"10.1016\/j.beem.2024.101955_bib4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jamaoto.2019.1110","article-title":"Characterization of malignant head and neck paragangliomas at a single institution across multiple decades","volume":"145","author":"McCrary","year":"2019","journal-title":"JAMA Otolaryngol Neck Surg"},{"issue":"6","key":"10.1016\/j.beem.2024.101955_bib5","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2024.101955_bib6","doi-asserted-by":"crossref","first-page":"690","DOI":"10.4158\/EP161718.RA","article-title":"Precision medicine: an update on genotype\/biochemical phenotype relationships in pheochromocytoma\/paraganglioma patients","volume":"23","author":"Gupta","year":"2017","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.beem.2024.101955_bib7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jacc.2020.04.080","article-title":"Pathophysiology and acute management of tachyarrhythmias in pheochromocytoma: JACC review topic of the week","volume":"76","author":"Nazari","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.beem.2024.101955_bib8","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1210\/jc.2018-01707","article-title":"Pheochromocytoma characteristics and behavior differ depending on method of discovery","volume":"104","author":"Gruber","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2024.101955_bib9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMra1806651","article-title":"Pheochromocytoma and paraganglioma","volume":"381","author":"Neumann","year":"2019","journal-title":"N Engl J Med"},{"issue":"9486","key":"10.1016\/j.beem.2024.101955_bib10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","article-title":"Phaeochromocytoma","volume":"366","author":"Lenders","year":"2005","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.beem.2024.101955_bib11","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.beem.2024.101955_bib12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1210\/clinem\/dgac563","article-title":"Recurrent disease in patients with sporadic pheochromocytoma and paraganglioma","volume":"108","author":"Li","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2024.101955_bib13","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1210\/jc.2002-030005","article-title":"Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results","volume":"88","author":"Eisenhofer","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"24","key":"10.1016\/j.beem.2024.101955_bib14","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJM199906173402404","article-title":"Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel\u2013Lindau disease and multiple endocrine neoplasia type 2","volume":"340","author":"Eisenhofer","year":"1999","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beem.2024.101955_bib15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1210\/endrev\/bnae001","article-title":"Imaging of pheochromocytomas and paragangliomas","volume":"45","author":"Timmers","year":"2024","journal-title":"Endocr Rev"},{"issue":"10","key":"10.1016\/j.beem.2024.101955_bib16","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1056\/NEJMoa1205119","article-title":"Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia","volume":"367","author":"Zhuang","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beem.2024.101955_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030594","article-title":"New insights on the genetics of pheochromocytoma and paraganglioma and its clinical implications","volume":"14","author":"Jhawar","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.beem.2024.101955_bib18","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0050","article-title":"Pacak\u2013Zhuang syndrome: a model providing new insights into tumor syndromes","volume":"30","author":"Rosenblum","year":"2023","journal-title":"Endocr-Relat Cancer"},{"issue":"2","key":"10.1016\/j.beem.2024.101955_bib19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"issue":"20","key":"10.1016\/j.beem.2024.101955_bib20","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1093\/hmg\/ddr324","article-title":"Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma","volume":"20","author":"Burnichon","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"10","key":"10.1016\/j.beem.2024.101955_bib21","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1210\/clinem\/dgaa502","article-title":"Sino-European differences in the genetic landscape and clinical presentation of pheochromocytoma and paraganglioma","volume":"105","author":"Jiang","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.beem.2024.101955_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11864-020-00787-z","article-title":"Emerging treatments for advanced\/metastatic pheochromocytoma and paraganglioma","volume":"21","author":"Ilanchezhian","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.beem.2024.101955_bib23","article-title":"Personalized management of pheochromocytoma and paraganglioma","author":"N\u00f6lting","year":"2021","journal-title":"Endocr Rev"},{"key":"10.1016\/j.beem.2024.101955_bib24","article-title":"Genotype-phenotype correlations in pheochromocytoma and paraganglioma","volume":"1","author":"Crona","year":"2019","journal-title":"Endocr-Relat Cancer"},{"issue":"2","key":"10.1016\/j.beem.2024.101955_bib25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00441-017-2760-3","article-title":"Pheochromocytoma and paraganglioma: genotype versus anatomic location as determinants of tumor phenotype","volume":"372","author":"Fliedner","year":"2018","journal-title":"Cell Tissue Res"},{"issue":"1","key":"10.1016\/j.beem.2024.101955_bib26","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41467-023-36769-6","article-title":"Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma","volume":"14","author":"Calsina","year":"2023","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.beem.2024.101955_bib27","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1002\/ijc.28868","article-title":"Opposing effects of HIF1\u03b1 and HIF2\u03b1 on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC\u2010associated factor X","volume":"135","author":"Qin","year":"2014","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.beem.2024.101955_bib28","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3390\/cancers11050594","article-title":"Impact of extrinsic and intrinsic hypoxia on catecholamine biosynthesis in absence or presence of HIF2\u03b1 in pheochromocytoma cells","volume":"11","author":"Bechmann","year":"2019","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.beem.2024.101955_bib29","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1677\/erc.1.00838","article-title":"Distinct gene expression profiles in norepinephrine-and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel\u2013Lindau syndrome","volume":"11","author":"Eisenhofer","year":"2004","journal-title":"Endocr-Relat Cancer"},{"key":"10.1016\/j.beem.2024.101955_bib30","article-title":"Regulation of epinephrine biosynthesis in HRAS-mutant paragangliomas","volume":"1","author":"Li","year":"2023","journal-title":"Endocr-Relat Cancer"},{"issue":"2","key":"10.1016\/j.beem.2024.101955_bib31","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/qjmed\/77.2.1151","article-title":"Clinical features and natural history of von Hippel-Lindau disease","volume":"77","author":"Maher","year":"1990","journal-title":"QJM: Int J Med"},{"issue":"6","key":"10.1016\/j.beem.2024.101955_bib32","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1056\/NEJMra1011165","article-title":"Oxygen sensing, homeostasis, and disease","volume":"365","author":"Semenza","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.beem.2024.101955_bib33","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.devcel.2009.11.008","article-title":"The role of hypoxia in development of the Mammalian embryo","volume":"17","author":"Dunwoodie","year":"2009","journal-title":"Dev Cell"},{"issue":"4","key":"10.1016\/j.beem.2024.101955_bib34","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","article-title":"Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway","volume":"30","author":"Kaelin","year":"2008","journal-title":"Mol Cell"},{"issue":"6733","key":"10.1016\/j.beem.2024.101955_bib35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.beem.2024.101955_bib36","doi-asserted-by":"crossref","first-page":"9361","DOI":"10.1128\/MCB.23.24.9361-9374.2003","article-title":"Differential roles of hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1) and HIF-2\u03b1 in hypoxic gene regulation","volume":"23","author":"Hu","year":"2003","journal-title":"Mol Cell Biol"},{"issue":"12","key":"10.1016\/j.beem.2024.101955_bib37","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1158\/0008-5472.CAN-05-2519","article-title":"Role of hypoxia-inducible factor (HIF)-1\u03b1 versus HIF-2\u03b1 in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway","volume":"66","author":"Carroll","year":"2006","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.beem.2024.101955_bib38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1096\/fj.02-0445fje","article-title":"Widespread, hypoxia\u2010inducible expression of HIF\u20102\u03b1 in distinct cell populations of different organs","volume":"17","author":"Wiesener","year":"2003","journal-title":"FASEB J"},{"issue":"37","key":"10.1016\/j.beem.2024.101955_bib39","doi-asserted-by":"crossref","first-page":"38458","DOI":"10.1074\/jbc.M406026200","article-title":"Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor","volume":"279","author":"Appelhoff","year":"2004","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.beem.2024.101955_bib40","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ccr.2006.08.026","article-title":"Recruitment of HIF-1\u03b1 and HIF-2\u03b1 to common target genes is differentially regulated in neuroblastoma: HIF-2\u03b1 promotes an aggressive phenotype","volume":"10","author":"Holmquist-Mengelbier","year":"2006","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.beem.2024.101955_bib41","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1158\/0008-5472.CAN-10-4142","article-title":"The hypoxia-associated factor switches cells from HIF-1\u03b1-to HIF-2\u03b1-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion","volume":"71","author":"Koh","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.beem.2024.101955_bib42","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae038","article-title":"Patient sex and origin influence distribution of driver genes and clinical presentation of paraganglioma","author":"Richter","year":"2024","journal-title":"J Endocr Soc"},{"issue":"8","key":"10.1016\/j.beem.2024.101955_bib43","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-23-0303","article-title":"EPAS1-related pheochromocytoma\/paraganglioma","volume":"31","author":"Alzahrani","year":"2024","journal-title":"Endocr-Relat Cancer"},{"issue":"8","key":"10.1016\/j.beem.2024.101955_bib44","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/jmedgenet-2018-105714","article-title":"Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma","volume":"56","author":"Ben Aim","year":"2019","journal-title":"J Med Genet"},{"issue":"11","key":"10.1016\/j.beem.2024.101955_bib45","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/hmg\/ddt069","article-title":"Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis","volume":"22","author":"Comino-M\u00e9ndez","year":"2013","journal-title":"Hum Mol Genet"},{"issue":"10","key":"10.1016\/j.beem.2024.101955_bib46","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/jmedgenet-2015-103218","article-title":"Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients","volume":"52","author":"Curr\u00e1s-Freixes","year":"2015","journal-title":"J Med Genet"},{"issue":"3","key":"10.1016\/j.beem.2024.101955_bib47","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1530\/ERC-13-0101","article-title":"In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas","volume":"20","author":"Toledo","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"10.1016\/j.beem.2024.101955_bib48","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1530\/ERC-20-0205","article-title":"HIF2\u03b1 supports pro-metastatic behavior in pheochromocytomas\/paragangliomas","volume":"27","author":"Bechmann","year":"2020","journal-title":"Endocr-Relat Cancer"},{"key":"10.1016\/j.beem.2024.101955_bib49","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1530\/ERC-13-0384","article-title":"Frequent EPAS1\/HIF2a exons 9 and 12 mutations in non-familial pheochromocytoma","volume":"21","author":"Welander","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.beem.2024.101955_bib50","doi-asserted-by":"crossref","first-page":"e1835","DOI":"10.1210\/clinem\/dgac058","article-title":"Genetic characteristics of incidental pheochromocytoma and paraganglioma","volume":"107","author":"Zhang","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2024.101955_bib51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/ERC-20-0280","article-title":"Functional significance of germline EPAS1 variants","volume":"28","author":"Dwight","year":"2021","journal-title":"Endocr-Relat Cancer"},{"issue":"4","key":"10.1016\/j.beem.2024.101955_bib52","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00109-012-0967-z","article-title":"A novel EPAS1\/HIF2A germline mutation in a congenital polycythemia with paraganglioma","volume":"91","author":"Lorenzo","year":"2013","journal-title":"J Mol Med"},{"issue":"11","key":"10.1016\/j.beem.2024.101955_bib53","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO\u2013EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.beem.2024.101955_bib54","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-PronO study): a European network for the study of adrenal tumors retrospective study","volume":"104","author":"Hescot","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101955_bib55","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejca.2022.03.032","article-title":"Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma","volume":"169","author":"Pamporaki","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.beem.2024.101955_bib56","article-title":"Hypoxia-inducible factor 2\u03b1: a key player in tumorigenesis and metastasis of pheochromocytoma and paraganglioma?","author":"Bechmann","year":"2021","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"2","key":"10.1016\/j.beem.2024.101955_bib57","doi-asserted-by":"crossref","first-page":"E369","DOI":"10.1210\/jc.2013-2600","article-title":"Mosaicism in HIF2A-related polycythemia-paraganglioma syndrome","volume":"99","author":"Buffet","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.beem.2024.101955_bib58","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1530\/ERC-16-0231","article-title":"Novel insights into the polycythemia\u2013paraganglioma\u2013somatostatinoma syndrome","volume":"23","author":"D\u00e4rr","year":"2016","journal-title":"Endocr-Relat Cancer"},{"issue":"2","key":"10.1016\/j.beem.2024.101955_bib59","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamaophthalmol.2019.5244","article-title":"Vascular changes in the retina and choroid of patients with EPAS1 gain-of-function mutation syndrome","volume":"138","author":"Dmitriev","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"22","key":"10.1016\/j.beem.2024.101955_bib60","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMc1211953","article-title":"HIF2A mutations in paraganglioma with polycythemia","volume":"367","author":"Favier","year":"2012","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.beem.2024.101955_bib61","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1200\/JCO.2012.47.1912","article-title":"New syndrome of paraganglioma and somatostatinoma associated with polycythemia","volume":"31","author":"Pacak","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beem.2024.101955_bib62","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.3390\/ijms20112819","article-title":"Chiari malformation type 1 in EPAS1-associated syndrome","volume":"20","author":"Rosenblum","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.beem.2024.101955_bib63","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.144368","article-title":"Developmental vascular malformations in EPAS1 gain-of-function syndrome","volume":"6","author":"Rosenblum","year":"2021","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.beem.2024.101955_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/hgv.2015.53","article-title":"Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia","volume":"2","author":"Yang","year":"2015","journal-title":"Hum Genome Var"},{"issue":"13","key":"10.1016\/j.beem.2024.101955_bib65","first-page":"2563","article-title":"Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas","volume":"121","author":"Yang","year":"2013","journal-title":"Blood J Am Soc Hematol"},{"issue":"11","key":"10.1016\/j.beem.2024.101955_bib66","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.ophtha.2014.06.019","article-title":"Ocular manifestations of HIF-2 \u03b1 paraganglioma-somatostatinomapolycythemia syndrome","volume":"121","author":"Pacak","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.beem.2024.101955_bib67","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s42003-024-05904-4","article-title":"Deficiency in PHD2-mediated hydroxylation of HIF2\u03b1 underlies Pacak-Zhuang syndrome","volume":"7","author":"Ferens","year":"2024","journal-title":"Commun Biol"},{"issue":"1","key":"10.1016\/j.beem.2024.101955_bib68","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1038\/s41467-018-05554-1","article-title":"HIF-2\u03b1-pVHL complex reveals broad genotype-phenotype correlations in HIF-2\u03b1-driven disease","volume":"9","author":"Tarade","year":"2018","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.beem.2024.101955_bib69","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3390\/genes11111254","article-title":"Identification of novel mutations and expressions of EPAS1 in phaeochromocytomas and paragangliomas","volume":"11","author":"Islam","year":"2020","journal-title":"Genes"},{"issue":"3","key":"10.1016\/j.beem.2024.101955_bib70","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000414","article-title":"Neuraxial dysraphism in EPAS1-associated syndrome due to improper mesenchymal transition","volume":"6","author":"Rosenblum","year":"2020","journal-title":"Neurol Genet"},{"issue":"7","key":"10.1016\/j.beem.2024.101955_bib71","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28981","article-title":"Pseudohypoxic pheochromocytomas and paragangliomas dominate in children","volume":"68","author":"Redlich","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.beem.2024.101955_bib72","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s00439-003-0969-6","article-title":"Altitude is a phenotypic modifier in hereditary paraganglioma type 1: evidence for an oxygen-sensing defect","volume":"113","author":"Astrom","year":"2003","journal-title":"Hum Genet"},{"issue":"3","key":"10.1016\/j.beem.2024.101955_bib73","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/bjh.19278","article-title":"EPAS1\u2010mutated paragangliomas associated with haemoglobin disorders","volume":"204","author":"Mancini","year":"2024","journal-title":"Br J Haematol"},{"issue":"13","key":"10.1016\/j.beem.2024.101955_bib74","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1056\/NEJMc1716652","article-title":"EPAS1 mutations and paragangliomas in cyanotic congenital heart disease","volume":"378","author":"Vaidya","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beem.2024.101955_bib75","doi-asserted-by":"crossref","unstructured":"Edwards C, Heath D, Harris P, et al. The carotid body in animals at high altitude. 1971.","DOI":"10.1002\/path.1711040404"},{"issue":"2","key":"10.1016\/j.beem.2024.101955_bib76","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0046-8177(73)80012-7","article-title":"High altitude hypoxia and chemodectomas","volume":"4","author":"Saldana","year":"1973","journal-title":"Hum Pathol"},{"issue":"16","key":"10.1016\/j.beem.2024.101955_bib77","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1158\/1078-0432.CCR-10-0637","article-title":"Mutation of SDHB is a cause of hypoxia-related high-altitude paraganglioma","volume":"16","author":"Cerecer-Gil","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.beem.2024.101955_bib78","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jvs.2007.10.040","article-title":"Carotid body tumor in a 13-year-old child: case report and review of the literature","volume":"47","author":"Georgiadis","year":"2008","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.beem.2024.101955_bib79","article-title":"Convergent genetic adaptation in human tumors developed under systemic hypoxia and in populations living at high altitudes","author":"Arenillas","year":"2024","journal-title":"bioRxiv"},{"issue":"9","key":"10.1016\/j.beem.2024.101955_bib80","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1210\/clinem\/dgac362","article-title":"Genetic analysis of pheochromocytoma and paraganglioma complicating cyanotic congenital heart disease","volume":"107","author":"Ogasawara","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.beem.2024.101955_bib81","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1093\/pubmed\/fdx172","article-title":"How many people have sickle cell disease in the UK?","volume":"40","author":"Dormandy","year":"2018","journal-title":"J Public Health"},{"issue":"2","key":"10.1016\/j.beem.2024.101955_bib82","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/14767050500233266","article-title":"Pheochromocytoma in a patient with sickle-\u03b2-thalassemia","volume":"18","author":"M\u00fcssig","year":"2005","journal-title":"J Matern-Fetal Neonatal Med"},{"issue":"1","key":"10.1016\/j.beem.2024.101955_bib83","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijoa.2004.07.012","article-title":"Anaesthesia for phaeochromocytoma and sickle cell disease in pregnancy","volume":"14","author":"Browne","year":"2005","journal-title":"Int J Obstet Anesth"},{"issue":"4","key":"10.1016\/j.beem.2024.101955_bib84","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ajh.10427","article-title":"Malignancy in patients with sickle cell disease","volume":"74","author":"Schultz","year":"2003","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.beem.2024.101955_bib85","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1365-2044.1990.tb14630.x","article-title":"Caesarean section in a patient with haemoglobin SC disease and a phaeochromocytoma","volume":"45","author":"Pattison","year":"1990","journal-title":"Anaesthesia"},{"issue":"3","key":"10.1016\/j.beem.2024.101955_bib86","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/phmj.phmj_12_19","article-title":"Two nights in one day: a case report of paraganglioma in sickle cell disease and a review of the literature","volume":"13","author":"Egigba","year":"2019","journal-title":"Port Harcourt Med J"},{"issue":"3","key":"10.1016\/j.beem.2024.101955_bib87","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2257.2002.00442.x","article-title":"A case of sickle\u2010cell erythrocytosis occurring following renal transplantation","volume":"24","author":"Myers","year":"2002","journal-title":"Clin Lab Haematol"},{"issue":"22","key":"10.1016\/j.beem.2024.101955_bib88","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1182\/blood.V128.22.4867.4867","article-title":"Malignancy in patients with sickle cell disease: a single center observational study","volume":"128","author":"Thomas","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beem.2024.101955_bib89","doi-asserted-by":"crossref","first-page":"E370","DOI":"10.1177\/000313481908500801","article-title":"A rare case of malignant peri-aortic paraganglioma","volume":"85","author":"Fancher","year":"2019","journal-title":"Am Surg"},{"issue":"5","key":"10.1016\/j.beem.2024.101955_bib90","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/jmf.14.5.353.355","article-title":"Pheochromocytoma, sickle cell disease and pregnancy: a case report","volume":"14","author":"Donnelly","year":"2003","journal-title":"J Matern-Fetal Neonatal Med"},{"key":"10.1016\/j.beem.2024.101955_bib91","first-page":"dgad311","article-title":"Somatic EPAS1 variants in phaeochromocytoma and paraganglioma in patients with sickle cell disease","author":"White","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2024.101955_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.eprac.2023.07.027","article-title":"Diagnosis and management of pheochromocytomas and paragangliomas: a guide for the clinician","author":"Sharma","year":"2023","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.beem.2024.101955_bib93","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/cancers13030385","article-title":"HIF2alpha-associated pseudohypoxia promotes radioresistance in pheochromocytoma: insights from 3D models","volume":"13","author":"Seifert","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.beem.2024.101955_bib94","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1073\/pnas.0808092106","article-title":"Artificial ligand binding within the HIF2\u03b1 PAS-B domain of the HIF2 transcription factor","volume":"106","author":"Scheuermann","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.beem.2024.101955_bib95","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.2508","article-title":"A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors","author":"Papadopoulos","year":"2018","journal-title":"Am Soc Clin Oncol"},{"issue":"22","key":"10.1016\/j.beem.2024.101955_bib96","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa2110051","article-title":"Belzutifan, a potent HIF2\u03b1 Inhibitor, in the Pacak\u2013Zhuang syndrome","volume":"385","author":"Kamihara","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beem.2024.101955_bib97","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1210\/endrev\/bnac025","article-title":"Hypoxia-inducible factor 2 alpha (HIF2\u03b1) inhibitors: targeting genetically driven tumor hypoxia","volume":"44","author":"Toledo","year":"2023","journal-title":"Endocr Rev"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24001313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X24001313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:04:01Z","timestamp":1778616241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X24001313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":97,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1521690X24001313"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2024.101955","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current views on the role of HIF-2\u03b1 in the pathogenesis and syndromic presentation of pheochromocytoma and paraganglioma","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2024.101955","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101955"}}